Topline Phase 3 Data: Guselkumab (Tremfya, Janssen Pharmaceuticals) Cools Inflammation and Halts Disease Progression in PsA April 7, 2025
A Bridge Over Troubled Water: Art Garfunkel Opens Up About Finding the Right PsO Treatment as Part of New Partnership With Sun Pharma April 4, 2025
The Search for Steroid-sparing Options in PsO: PEPITEM and Its Tripeptide Sequence Shows Promise April 3, 2025
ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan March 27, 2025
PsO Pipeline Watch: Alumis Inc.’s Oral TYK2 inhibitor, ESK-001, Boasts High Clearance Rates at One Year; Q & A With Dr.Andrew Blauvelt March 12, 2025
Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms and QofL for GPP Patients March 8, 2025
First Patient Dosed in Phase 1b Trial of VYNE’s BET Inhibitor in Moderate-to-severe PsO February 20, 2025
Unpacking the New Expert Consensus Panel Recommendations on the Use of Deucravacitinib (Sotyktu, BMS) in Psoriasis February 11, 2025
